Soluble human major histocompatibility class I antigens: new immunomodulatory functions for old molecules

References

• Van Rood JJ, van Leeuwen A, van Santen MCT. Anti HL-A2 inhibitor in normal human serum. Nature 226, 366–367 (1970).
   PubMed Web of Science ®Google Scholar
• Charlton RK, Zmijewski CM. Soluble HL-A7 antigen: localization in the β-lipoprotein fraction of human serum. Science 170, 636–637 (1970).
   PubMed Web of Science ®Google Scholar
• Puppo F, Brenci S, Lanza L et al. Increased level of serum HLA Class I antigens in HIV infection. Correlation with disease progression. Hum. Immunol. 40, 259–266 (1994).
   PubMed Web of Science ®Google Scholar
• Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA Class I antigens: markers and modulators of an immune response? Immunol. Today 16, 124–127 (1995).
   PubMedGoogle Scholar
• Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in maternal blood during pregnancy. Am. J. Obstet. Gynecol. 183, 682–688 (2000).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-α immunotherapy. Cancer 92, 369–376 (2001).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Feger U, Mittelbronn M et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 128, 2689–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Leleu X, Le Friec G, Facon T et al. on behalf of the Intergroupe Francophone du Myelome. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Cancer Res. 11, 7297–7303 (2005).
   PubMed Web of Science ®Google Scholar
• Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol. Today 18, 154–155 (1997).
   PubMedGoogle Scholar
• Ghio M, Contini P, Mazzei C et al. Soluble HLA class I, HLA class II and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 93, 1770–1777 (1999).
   PubMed Web of Science ®Google Scholar
• Ghio M, Contini P, Mazzei C et al. Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions. Leuk. Lymphoma 37, 1–8 (2000).
   PubMedGoogle Scholar
• Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F. Fas, Fas ligand, and transfusion immunomodulation. Transfusion 41, 416–418 (2001).
   PubMedGoogle Scholar
• Ghio M, Contini P, Mazzei C et al. In vitro immunosuppressive activity of soluble HLA Class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion 41, 988–996 (2001).
   PubMed Web of Science ®Google Scholar
• Hausmann R, Zavazava N, Steinmann J, Müller-Ruchholtz W. Interaction of papain digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin. Exp. Immunol. 91, 183–188 (1993).
   PubMed Web of Science ®Google Scholar
• Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnik GK, Krensky AM. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2 domain of HLA-A2. Nature 325, 625–628 (1987).
   PubMed Web of Science ®Google Scholar
• Dal Porto J, Johansen TE, Catipovic B. A soluble divalent Class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc. Natl Acad. Sci. USA 90, 6671–6675 (1993).
   PubMed Web of Science ®Google Scholar
• Zavazava N, Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nature Med. 2, 1005–1010 (1996).
   PubMed Web of Science ®Google Scholar
• Contini P, Ghio M, Merlo A et al. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Hum. Immunol. 61, 1347–1351 (2000).
   PubMed Web of Science ®Google Scholar
• Gansuvd B, Haghiara M, Munkhbat B et al. Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro. Clin. Exp. Immunol. 119, 107–114 (2000).
   PubMedGoogle Scholar
• Puppo F, Contini P, Ghio M et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas(CD95)+ T lymphocytes. Int. Immunol. 12, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Contini P, Carosio R et al. Soluble HLA class I molecules induce Natural Killer cell apoptosis through the engagement of CD8. Evidence for a negative regulation exerted by CD94/NKG2A complex and KIR2D. Blood 99, 1706–1714 (2002).
   PubMedGoogle Scholar
• Spaggiari GM, Contini P, Dondero A et al. Soluble HLA Class I induces NK cell apoptosis upon the engagement of killer activating HLA class I receptors through FasL/Fas interaction. Blood 100, 4098–4107 (2002).
   PubMedGoogle Scholar
• Fournel S, Aguerre-Girr M, Huc X et al. Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interaction with CD8. J. Immunol. 164, 6100–6104 (2000).
   PubMed Web of Science ®Google Scholar
• Contini P, Ghio M, Poggi A et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 33, 125–134 (2003).
   Google Scholar
• Contini P, Ghio M, Merlo M, Poggi A, Indiveri F, Puppo F. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA Class I molecules is Fas Ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for. NF-ĸκB and NF-AT nuclear translocation. J. Immunol. 175, 7244–7254 (2005).
   PubMed Web of Science ®Google Scholar
• Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J. Regulation of apoptosis in immune cells. J. Clin. Immunol. 15, 1–16 (1995).
   PubMed Web of Science ®Google Scholar
• van Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8, 355–361 (1996).
   PubMed Web of Science ®Google Scholar
• Yonehara S, Nishimura Y, Kishil S et al. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int. Immunol. 6, 1849–1856 (1994).
   PubMed Web of Science ®Google Scholar
• Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16, 569–574 (1995).
   PubMedGoogle Scholar
• Kurts C, Heath WR, Kosaka H, Miller JFAP, Carbone F. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J. Exp. Med. 188, 415–420 (1998).
   PubMedGoogle Scholar